Skip to content
Screener

Relay Therapeutics, Inc. RLAY Operating Income

Operating Income at other companies

Schrodinger logo
SchrodingerSDGR
-$41.55M+21.5%
PVL
Palvella TherapeuticsPVLA
-$14.86M-88.7%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
-$134.97M+23.4%
Celcuity logo
CelcuityCELC
-$50.51M-39.8%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$505.13M-90.8%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$8.59M+1.7%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K—
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.3B+611%
Enterprise value$4.21B+702%
P/S415.9×+343×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0×0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development expenses$76,483$63,897$147,046$137,706
General and administrative expenses14,69113,62725,71832,366
Total operating expenses91,17477,524172,764170,072
Loss from operations(90,824)(76,847)(169,414)(161,717)
Other income:
Interest income7,1157,10512,46714,918
Other income (expense)2(633)(51)(641)
Total other income, net7,1176,47212,41614,277

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s operating income?
Relay Therapeutics, Inc. (RLAY) reported operating income of -$90.82M in Q2 2026.
How has Relay Therapeutics, Inc.'s operating income changed year-over-year?
Relay Therapeutics, Inc.'s operating income decreased by 18.2% year-over-year, from -$76.85M to -$90.82M.
What is the long-term trend for Relay Therapeutics, Inc.'s operating income?
Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s operating income has grown at a -4.5% compound annual growth rate (CAGR), from -$364.7M to -$302.74M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Relay Therapeutics, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude